Arena Capital Advisors’s Pardes Biosciences, Inc. Common Stock PRDS Stock Holding History

Arena Capital Advisors’s Portfolio PRDS Stock Details PRDS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-826,104	Closed	-$1.5M	–	60
2023 Q2	$1.5M	Sell	826,104 -25,177	-3%	-$46K	5%	5
2023 Q1	$1.12M	Hold	851,281	–	–	1.57%	15
2022 Q4	$1.44M	Hold	851,281	–	–	0.79%	37
2022 Q3	$1.57M	Hold	851,281	–	–	0.48%	61
2022 Q2	$2.61M	Hold	851,281	–	–	0.66%	55
2022 Q1	$6.15M	Sell	851,281 -336,168	-28%	-$3.31M	0.93%	35
2021 Q4	$19.4M	Sell	1,187,449 -858,149	-42%	-$9.98M	1.79%	7
2021 Q3	$20.4M	Buy	2,045,598 +532,393	+35%	+$5.29M	1.61%	7
2021 Q2	$15.1M	Buy	1,513,205 +1,182,588	+358%	+$11.9M	1.25%	9
2021 Q1	$3.29M	Buy	+330,617	New	+$3.42M	0.33%	101

Other funds holding PRDS

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Arena Capital Advisors's PRDS Position: Q3 2023 in Review

Arena Capital Advisors sold out of Pardes Biosciences, Inc. Common Stock (PRDS) in Q3 2023, closing a stake of 826,104 shares — an estimated $1.5M sold.

Arena Capital Advisors first reported a position in PRDS in Q1 2021 and held it in 10 quarters. The position peaked at $20.4M in Q3 2021. 1 fund tracked by Wall St. Rank holds PRDS as of Q3 2023.

Arena Capital Advisors reported no remaining Pardes Biosciences, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Arena Capital Advisors sold 826,104 Pardes Biosciences, Inc. Common Stock shares in Q3 2023, an estimated $1.5M.
Arena Capital Advisors first reported a position in Pardes Biosciences, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
Arena Capital Advisors's Pardes Biosciences, Inc. Common Stock position peaked at $20.4M in Q3 2021.
1 fund tracked by Wall St. Rank held Pardes Biosciences, Inc. Common Stock as of Q3 2023.

Based on Arena Capital Advisors's 13F filing for Q3 2023, filed 7 Nov 2023.